Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial

Kidney International

Volumn 60, Issue 5, 2001, Pages 1990-1997

  Holdaas, Hallvard ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Jardine, Alan G ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Wheeler, David C ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Brekke, Inge B ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Conlon, Peter J ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Fellstrøm, Bengt ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Hammad, Abdel ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Holme, Ingar ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Isoniemi, Helena ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Moore, Richard ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Rowe, Peter A ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Sweny, Paul ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Talbot, David A ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Wadstrøm, Jonas ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   østraat, ØYvind ^{a,b,c,d,e,f,g,h,i,j,k,l,m}  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b WESTERN INFIRMARY   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d BEAUMONT HOSPITAL   (Ireland)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ Cardiff Royal Infirmary   (United Kingdom)

^j DERRIFORD HOSPITAL   (United Kingdom)

^k ROYAL FREE HOSPITAL   (United Kingdom)

^l FREEMAN HOSPITAL   (United Kingdom)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Acute rejection; Cyclosporine A; Dyslipidemia; End stage renal failure; HMG CoA reductase inhibition; Kidney transplantation

Indexed keywords

FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS;

EID: 0034778828     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00010.x     Document Type: Article

References (30)

1. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study Group
4. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS study
6. Pravastatin therapy and the risk of stroke
7. Prenylation inhibitors in renal disease
8. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
9. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
10. Inhibitors of hydroxy-methylglutaryl-coenzyme A reductase and risk of fracture among older women
11. Effects of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
12. The effect of pravastatin on acute rejection after kidney transplantation - A pilot study
13. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
14. Effect of pravastatin on outcomes after cardiac transplantation
15. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection
16. Effects of Pravastatin on chronic rejection of rat cardiac allografts
17. Inhibition of monocyte chemotactic protein-1 synthesis by statins
18. Effects of lovastatin on natural killer cell function and other immunological parameters in man
19. Interrelationships between mevalonate metabolism and the mitogenic signalling pathway in T lymphocyte proliferation
20. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
21. Statins as a newly recognized type of immunomodulator
22. The adverse impact of cyclosporine on serum lipids in renal transplant recipients
23. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients
24. Cardiovascular morbidity and risk factors in renal transplant patients
25. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine
26. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
27. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of the clinical and safety experience
28. Clinical validation and reproducibility of the Banff Schema for renal allograft pathology
29. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants
30. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipiets